Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas Results will likely "encourage a practice change," editorialists say May 10, 2023
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's Findings may bolster interest in BTK inhibitors for autoimmune diseases May 02, 2023
Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS Apr 20, 2023
Sam Neill's Rare Lymphoma The actor noticed swollen glands while on tour for "Jurassic World Dominion" Mar 23, 2023
FDA Panel Endorses New First-Line Lymphoma Regimen POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say Mar 10, 2023
FDA Not Quite Sold on Polivy in Frontline Large B-Cell Lymphoma Regimen Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty" Mar 07, 2023
Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
Atorvastatin Tied to Cardioprotection for Lymphoma Patients on Anthracyclines STOP-CA deemed "an impactful study that will lead to more prescription of statins in patients." Mar 04, 2023
Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignancies Most patients had no recurrence of their original intolerance event Jan 10, 2023
Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphoma European trial is "practice-changing as of today," says U.S. expert Dec 13, 2022
Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody Most complete responses lasted 24 months or longer after limited-duration glofitamab Dec 13, 2022
Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging Data from St. Jude cohort show higher rates of neurocognitive impairment Dec 13, 2022
Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
Jane Fonda's Non-Hodgkin Lymphoma The award-winning actress opened up about her latest health news Sep 06, 2022
What Caused Man's Saddle-Nose Deformity Years After Lymphoma Dx? Rare diagnosis points to need for thorough workup in patients with severe nasal congestion Aug 01, 2022
Breast Implant-Related Lymphoma More Common Than Reported Contemporary data suggest at least a twofold higher case rate as compared with FDA estimates Jul 21, 2022
Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma More than half of patients achieved complete responses with lisocabtagene maraleucel Jul 18, 2022
Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessment Information useful in fewer than 1% of patients with untreated disease Jul 10, 2022
Zanubrutinib Wins in First-Line CLL for Older Patients The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
FDA Warns of Increased Mortality Risk With Duvelisib Drug approved for adults with CLL/SLL Jul 01, 2022
Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphoma ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment Jun 21, 2022
Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone Jun 05, 2022
Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphoma Combo regimen offers "a new standard for front-line therapy," researcher says Jun 04, 2022
Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patients BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years Jun 03, 2022
FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trial Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
FDA Concerned About Safety of Lymphoma Drug Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
